Comparative Pharmacology
Head-to-head clinical analysis: CYLERT versus METADATE CD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYLERT versus METADATE CD.
CYLERT vs METADATE CD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CNS stimulant; increases extracellular dopamine and norepinephrine levels by blocking their reuptake and enhancing release.
Methylphenidate is a central nervous system (CNS) stimulant. It blocks the reuptake of norepinephrine and dopamine into the presynaptic neuron, increasing their levels in the extraneuronal space. The precise mechanism for treating ADHD is not fully understood.
37.5 mg orally once daily in the morning; may increase by 18.75 mg weekly to a maximum of 112.5 mg/day.
20-60 mg orally once daily in the morning
None Documented
None Documented
Terminal elimination half-life is 12-30 hours in children (mean 19 hours) and 8-14 hours in adults; the long half-life supports once-daily dosing, but accumulation can occur with repeated dosing
Terminal elimination half-life: 6.8 hours (range 4.5-10.3 hours) for methylphenidate; clinical context: supports twice-daily dosing regimen
Primarily renal (80-90% as unchanged drug and metabolites, with 50-60% as unchanged pemoline), minor biliary/fecal elimination (<10%)
Renal: 78-97% as metabolites (primarily ritalinic acid), unchanged drug <1%; fecal: <2%
Category C
Category C
CNS Stimulant
CNS Stimulant